$BIOLQ
BIOLASE, INC

2023 Q3 Form 10-Q Financial Statement

#000095017023041449 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $10.92M $14.29M
YoY Change -9.07% 16.76%
Cost Of Revenue $7.175M $8.168M
YoY Change -24.99% 15.14%
Gross Profit $3.746M $6.118M
YoY Change 53.21% 19.0%
Gross Profit Margin 34.3% 42.83%
Selling, General & Admin $6.081M $8.546M
YoY Change -25.08% 0.04%
% of Gross Profit 162.33% 139.69%
Research & Development $1.362M $1.444M
YoY Change -31.18% -12.64%
% of Gross Profit 36.36% 23.6%
Depreciation & Amortization $560.0K $1.424M
YoY Change 359.02% 995.38%
% of Gross Profit 14.95% 23.28%
Operating Expenses $7.443M $9.990M
YoY Change -26.28% -2.02%
Operating Profit -$3.697M -$3.872M
YoY Change -51.68% -23.4%
Interest Expense -$598.0K -$583.0K
YoY Change 41.04% 35.58%
% of Operating Profit
Other Income/Expense, Net -$877.0K -$965.0K
YoY Change 16.47% 81.05%
Pretax Income -$4.574M -$4.837M
YoY Change -45.57% -13.44%
Income Tax $15.00K $31.00K
% Of Pretax Income
Net Earnings -$4.589M -$4.868M
YoY Change -45.28% -13.24%
Net Earnings / Revenue -42.02% -34.08%
Basic Earnings Per Share -$3.89 -$8.93
Diluted Earnings Per Share -$3.89 -$8.93
COMMON SHARES
Basic Shares Outstanding 1.044M 27.73M
Diluted Shares Outstanding 1.179M 545.0K

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.810M $6.930M
YoY Change -21.59% -64.55%
Cash & Equivalents $7.800M $6.900M
Short-Term Investments
Other Short-Term Assets $1.760M $2.170M
YoY Change -33.53% 5.14%
Inventory $13.82M $13.33M
Prepaid Expenses
Receivables $4.400M $5.700M
Other Receivables $0.00 $0.00
Total Short-Term Assets $27.78M $28.15M
YoY Change -18.0% -36.42%
LONG-TERM ASSETS
Property, Plant & Equipment $6.049M $6.371M
YoY Change 54.51% 364.02%
Goodwill $2.900M $2.900M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $279.0K
YoY Change 15.38% 15.77%
Total Long-Term Assets $10.96M $11.49M
YoY Change 22.03% 74.37%
TOTAL ASSETS
Total Short-Term Assets $27.78M $28.15M
Total Long-Term Assets $10.96M $11.49M
Total Assets $38.75M $39.63M
YoY Change -9.61% -22.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.178M $6.314M
YoY Change 44.31% 27.27%
Accrued Expenses $7.613M $7.734M
YoY Change 10.03% 19.02%
Deferred Revenue $2.191M $2.236M
YoY Change 17.17% -10.27%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.800M $0.00
YoY Change
Total Short-Term Liabilities $19.78M $18.38M
YoY Change 43.73% 31.78%
LONG-TERM LIABILITIES
Long-Term Debt $11.31M $11.90M
YoY Change -11.62% -6.5%
Other Long-Term Liabilities $78.00K $79.00K
YoY Change -70.0% -62.38%
Total Long-Term Liabilities $11.39M $11.98M
YoY Change -12.78% -7.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.78M $18.38M
Total Long-Term Liabilities $11.39M $11.98M
Total Liabilities $32.86M $32.29M
YoY Change 13.29% 10.44%
SHAREHOLDERS EQUITY
Retained Earnings -$311.5M -$306.9M
YoY Change 8.79% 10.42%
Common Stock $312.5M $314.1M
YoY Change 3.76% 4.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $332.0K $6.621M
YoY Change
Total Liabilities & Shareholders Equity $38.75M $39.63M
YoY Change -9.61% -22.07%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$4.589M -$4.868M
YoY Change -45.28% -13.24%
Depreciation, Depletion And Amortization $560.0K $1.424M
YoY Change 359.02% 995.38%
Cash From Operating Activities -$2.590M -$3.562M
YoY Change -60.43% -46.13%
INVESTING ACTIVITIES
Capital Expenditures $190.0K $357.0K
YoY Change -107.09% -230.29%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$190.0K -$357.0K
YoY Change -92.91% 30.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.760M 4.276M
YoY Change -1857.01% -11.82%
NET CHANGE
Cash From Operating Activities -2.590M -3.562M
Cash From Investing Activities -190.0K -357.0K
Cash From Financing Activities 3.760M 4.276M
Net Change In Cash 980.0K 357.0K
YoY Change -110.38% -117.53%
FREE CASH FLOW
Cash From Operating Activities -$2.590M -$3.562M
Capital Expenditures $190.0K $357.0K
Free Cash Flow -$2.780M -$3.919M
YoY Change -28.13% -38.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0000811240
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36385
dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0442441
dei Entity Address Address Line1
EntityAddressAddressLine1
27042 Towne Centre Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 270
dei Entity Address City Or Town
EntityAddressCityOrTown
Lake Forest
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92610
dei City Area Code
CityAreaCode
949
dei Local Phone Number
LocalPhoneNumber
361-1200
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BIOL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1043747
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6930000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4181000
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2183000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2164000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5717000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5841000
CY2023Q2 us-gaap Inventory Net
InventoryNet
13330000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15884000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2170000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3053000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
28147000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
28959000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6371000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q2 us-gaap Goodwill
Goodwill
2926000
CY2022Q4 us-gaap Goodwill
Goodwill
2926000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1910000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1768000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
279000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
255000
CY2023Q2 us-gaap Assets
Assets
39633000
CY2022Q4 us-gaap Assets
Assets
38186000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6314000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5786000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7734000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9210000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2236000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2111000
CY2023Q2 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
2100000
CY2022Q4 us-gaap Mediumterm Notes Current
MediumtermNotesCurrent
700000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18384000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17807000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
311000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
418000
CY2023Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
397000
CY2022Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
360000
CY2023Q2 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
11902000
CY2022Q4 us-gaap Mediumterm Notes Noncurrent
MediumtermNotesNoncurrent
13091000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1219000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1259000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
79000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
362000
CY2023Q2 us-gaap Liabilities
Liabilities
32292000
CY2022Q4 us-gaap Liabilities
Liabilities
33297000
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
720000
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1019000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77000
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1019000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
314119000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
301790000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-614000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-733000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306885000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-296168000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39633000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38186000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
8168000
CY2022Q2 us-gaap Cost Of Revenue
CostOfRevenue
7094000
us-gaap Cost Of Revenue
CostOfRevenue
15299000
us-gaap Cost Of Revenue
CostOfRevenue
12531000
CY2023Q2 us-gaap Gross Profit
GrossProfit
6118000
CY2022Q2 us-gaap Gross Profit
GrossProfit
5141000
us-gaap Gross Profit
GrossProfit
9454000
us-gaap Gross Profit
GrossProfit
9870000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6189000
CY2022Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5402000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10812000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10216000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2357000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2991000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3141000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4815000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5717000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1444000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1653000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3197000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
9990000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
10196000
us-gaap Operating Expenses
OperatingExpenses
18618000
us-gaap Operating Expenses
OperatingExpenses
19130000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3872000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5055000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9164000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9260000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-235000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-103000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-215000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-223000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-583000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-430000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1160000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-863000
CY2023Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-147000
CY2022Q2 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-147000
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
0
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-965000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-533000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1522000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1086000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4837000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5588000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10686000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10346000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
31000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
40000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5611000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
us-gaap Net Income Loss
NetIncomeLoss
-10386000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-222000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-263000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4829000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5833000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10598000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10649000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5611000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
us-gaap Net Income Loss
NetIncomeLoss
-10386000
CY2023Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
CY2022Q2 biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
0
biol Deemed Dividend On Convertible Preferred Stock
DeemedDividendOnConvertiblePreferredStock
217000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4868000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5611000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10717000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10603000
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.93
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.93
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-91.98
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-91.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.52
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-173.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-173.82
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
545000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
545000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
437000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
437000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8158000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
404000
CY2023Q2 biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
100000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4868000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4889000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8503000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
925000
biol Stock Issued During Period Value Common Stock Warrants Exercised
StockIssuedDuringPeriodValueCommonStockWarrantsExercised
114000
us-gaap Net Income Loss
NetIncomeLoss
-10717000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6621000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20599000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5849000
CY2022Q2 biol Phant Award Reclass
PhantAwardReclass
596000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
403000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5611000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-222000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21615000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25208000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5849000
biol Phant Award Reclass
PhantAwardReclass
596000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
611000
us-gaap Net Income Loss
NetIncomeLoss
-10386000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-263000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
21615000
us-gaap Profit Loss
ProfitLoss
-10717000
us-gaap Profit Loss
ProfitLoss
-10386000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1573000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
247000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
42000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
143000
us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
-42000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
214000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
131000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-78000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
224000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Share Based Compensation
ShareBasedCompensation
775000
us-gaap Share Based Compensation
ShareBasedCompensation
1100000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-82000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1986000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
163000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3602000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-713000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
236000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1903000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-232000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
18000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
230000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9220000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14633000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
944000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
578000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-944000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-578000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8502000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5849000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
2738000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
918000
biol Proceeds From Sale Of Common Stock Warrants
ProceedsFromSaleOfCommonStockWarrants
0
biol Principal Payment On Loan
PrincipalPaymentOnLoan
0
biol Principal Payment On Loan
PrincipalPaymentOnLoan
1000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
635000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12793000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4849000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
120000
biol Effect Of Exchange Rate Changes
EffectOfExchangeRateChanges
-264000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2749000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10626000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4181000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30175000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6930000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19549000
us-gaap Interest Paid Net
InterestPaidNet
930000
us-gaap Interest Paid Net
InterestPaidNet
743000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
5000
us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
17000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
12000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
46000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
159000
biol Cash Paid For Operating Leases
CashPaidForOperatingLeases
135000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
483000
biol Non Cash Right Of Use Assets Obtained In Exchange For Lease Obligation
NonCashRightOfUseAssetsObtainedInExchangeForLeaseObligation
532000
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
0
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
217000
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
10980000
biol Common Stock Issued Upon Exercise Of Preferred Stock
CommonStockIssuedUponExerciseOfPreferredStock
0
CY2023Q2 biol Working Capital
WorkingCapital
9800000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6900000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5700000
CY2022Q4 biol Working Capital
WorkingCapital
11200000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4200000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5800000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
600000
us-gaap Net Income Loss
NetIncomeLoss
-10700000
biol Capital Expenditures
CapitalExpenditures
900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents and trade accounts receivable. The Company maintains its cash and cash equivalents with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers’ financial condition and maintains relationships with the Company’s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of its products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Substantially all of the Company’s revenue is denominated in U.S. dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company’s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the three and six months ended June 30, 2023 and 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, respectively, the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S. dollar may affect the price competitiveness of the Company’s products outside the U.S.</span></p>
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
CY2023Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
CY2022Q2 biol Revenue From Products And Services Transferred To Customers Percentage
RevenueFromProductsAndServicesTransferredToCustomersPercentage
0.90
CY2023Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
CY2022Q2 biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
biol Revenue From Services Transferred To Customers Over Time Percentage
RevenueFromServicesTransferredToCustomersOverTimePercentage
0.10
CY2022Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2023Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
400000
CY2023Q2 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
431000
CY2022Q4 biol Contract With Customer Liability In Undelivered Elements
ContractWithCustomerLiabilityInUndeliveredElements
447000
CY2023Q2 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2116000
CY2022Q4 biol Contract With Customer Liability In Extended Warranty Contracts
ContractWithCustomerLiabilityInExtendedWarrantyContracts
2082000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2547000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2529000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
311000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
418000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2236000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2111000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
300000
biol Contract With Customer Liability Revenue Recognized Undelivered Elements
ContractWithCustomerLiabilityRevenueRecognizedUndeliveredElements
400000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1100000
biol Contract With Customer Liability Revenue Recognized Extended Warranty
ContractWithCustomerLiabilityRevenueRecognizedExtendedWarranty
1000000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7494.72
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
23791.67
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7419.6
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
CY2023Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
1000000000
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
1000000000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
413
CY2023Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
100000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
800000
CY2022Q2 biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
900000
biol Allocated Share Based Compensation Expense Credit
AllocatedShareBasedCompensationExpenseCredit
1100000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1000000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M6D
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
84000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
890000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
775000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1100000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7569.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M12D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriod
0
biol Share Based Compensation Arrangement By Share Based Payment Award Vested Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedOptionsExpirationsInPeriodWeightedAverageExercisePrice
0
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
1000000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4000
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
24000
biol Offering Of Common Stock
OfferingOfCommonStock
366154
biol Offering Of Common Stock
OfferingOfCommonStock
25919
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
6873000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
6697000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1841000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1871000
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4616000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7316000
CY2023Q2 us-gaap Inventory Net
InventoryNet
13330000
CY2022Q4 us-gaap Inventory Net
InventoryNet
15884000
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2100000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2200000
biol Inventory Reclassed To Property Plant And Equipment
InventoryReclassedToPropertyPlantAndEquipment
1700000
CY2023Q2 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
16328000
CY2022Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
12661000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10115000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8538000
CY2023Q2 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
6213000
CY2022Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4123000
CY2023Q2 us-gaap Land
Land
158000
CY2022Q4 us-gaap Land
Land
155000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6371000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2023Q2 biol Cumulative Adjustment Depreciation Expense
CumulativeAdjustmentDepreciationExpense
800000
biol Cumulative Adjustment Depreciation Expense
CumulativeAdjustmentDepreciationExpense
800000
CY2022 biol Decreased Inventory
DecreasedInventory
1700000
CY2022 us-gaap Property Plant And Equipment Gross Period Increase Decrease
PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
900000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q2 biol Discount Rate For Fair Value Level3
DiscountRateForFairValueLevel3
0.157
CY2023Q2 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2023Q2 us-gaap Goodwill
Goodwill
2900000
CY2022Q4 us-gaap Goodwill
Goodwill
2900000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3049000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4674000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1375000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1293000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
861000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
638000
CY2023Q2 biol Stock Warrant Liability
StockWarrantLiability
815000
CY2022Q4 biol Stock Warrant Liability
StockWarrantLiability
0
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
381000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
432000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
284000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
591000
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
166000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
490000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
803000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1092000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7734000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9210000
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1855000
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1138000
CY2022Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1653000
CY2021Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1086000
CY2023Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
802000
CY2022Q2 us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
910000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1960000
us-gaap Product Warranty Accrual Preexisting Increase Decrease
ProductWarrantyAccrualPreexistingIncreaseDecrease
1461000
CY2023Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
885000
CY2022Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
815000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1841000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1314000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1772000
CY2022Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1233000
CY2023Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1772000
CY2022Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1233000
CY2023Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
397000
CY2022Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
431000
CY2023Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
397000
CY2022Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
431000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1375000
CY2022Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
802000
CY2023Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1375000
CY2022Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
802000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
14002000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
13791000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11902000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13091000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
600000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
900000
CY2023Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.1396
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
700000
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfInterestRemainderOfFiscalYear
978000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2800000
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfInterestInNextTwelveMonths
1690000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
11150000
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfInterestInYearTwo
741000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfInterestInYearThree
9000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
150000
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest In Year After Five
LongTermDebtMaturitiesRepaymentsOfInterestInYearAfterFive
89000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
14800000
CY2023Q2 biol Long Term Debt Maturities Repayments Of Interest
LongTermDebtMaturitiesRepaymentsOfInterest
3507000
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
92000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
69000
us-gaap Operating Lease Payments
OperatingLeasePayments
159000
us-gaap Operating Lease Payments
OperatingLeasePayments
135000
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
19000
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
118000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
483000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
562000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.123
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1056000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
933000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
412000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
0
CY2023Q2 biol Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2401000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
321000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2080000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
861000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1219000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2080000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1900000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2100000
CY2023Q2 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
600000
CY2022Q2 us-gaap Payments For Rent
PaymentsForRent
300000
us-gaap Payments For Rent
PaymentsForRent
500000
CY2023Q2 biol Future Minimum Payments Remainder Of Fiscal Year
FutureMinimumPaymentsRemainderOfFiscalYear
532000
CY2023Q2 biol Future Minimum Payments Due In One Year
FutureMinimumPaymentsDueInOneYear
1049000
CY2023Q2 biol Future Minimum Payments Due In Two Years
FutureMinimumPaymentsDueInTwoYears
817000
CY2023Q2 biol Future Minimum Payments Due In Three Years
FutureMinimumPaymentsDueInThreeYears
3000
CY2023Q2 biol Future Minimum Payments Due Thereafter
FutureMinimumPaymentsDueThereafter
0
CY2023Q2 biol Future Minimum Payments Due
FutureMinimumPaymentsDue
2401000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
321000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2080000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6371000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4278000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14286000
CY2023Q2 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12235000
CY2022Q2 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24753000
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22401000
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
CY2022Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q2 biol Income Tax Provision
IncomeTaxProvision
31000
biol Income Tax Provision
IncomeTaxProvision
31000
CY2022Q2 biol Income Tax Benefit
IncomeTaxBenefit
23000
biol Income Tax Benefit
IncomeTaxBenefit
40000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
At a special meeting of BIOLASE stockholders held on July 20, 2023 (the "special meeting"), BIOLASE stockholders approved an amendment to BIOLASE’s Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of BIOLASE common stock, at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, the Board approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of BIOLASE common stock (the “2023 Reverse Stock Split”).

Files In Submission

Name View Source Status
0000950170-23-041449-index-headers.html Edgar Link pending
0000950170-23-041449-index.html Edgar Link pending
0000950170-23-041449.txt Edgar Link pending
0000950170-23-041449-xbrl.zip Edgar Link pending
biol-20230630.htm Edgar Link pending
biol-20230630.xsd Edgar Link pending
biol-ex10_1.htm Edgar Link pending
biol-ex10_2.htm Edgar Link pending
biol-ex31_1.htm Edgar Link pending
biol-ex31_2.htm Edgar Link pending
biol-ex32_1.htm Edgar Link pending
biol-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
biol-20230630_def.xml Edgar Link unprocessable
biol-20230630_lab.xml Edgar Link unprocessable
biol-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
biol-20230630_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
biol-20230630_cal.xml Edgar Link unprocessable